BMS Just Torched $100M on a Drug That Never Made It Past Phase 1

The company reviewed the clinical data and decided the program wasn't worth pursuing. The specifics of what went wrong haven't been disclosed publicly; BMS hasn't released detailed safety or efficacy numbers. But when a company walks away from a $100 million investment before a trial even finishes, the data clearly told a bad story.

Orum Keeps the Cash, Loses the Validation

For Orum Therapeutics, the financial damage is mixed. The company keeps the $100 million upfront payment, which is already in the bank. But it won't see any of the $80 million in milestones that were tied to the program's advancement. That's real money left on the table.

The bigger problem isn't financial; it's reputational. This deal was supposed to validate Orum's entire DAC platform in humans. Instead, it's now the second Orum DAC program to be discontinued (the first, ORM-5029, was shelved earlier). When your two most visible clinical programs both fail, investors and potential partners start asking hard questions about the underlying technology.

Orum still has cards to play. The company raised about $100 million in December 2025 to fund its pipeline, and it's advancing another program, ORM-1153, toward a regulatory filing in the second half of 2026. But the burden of proof just got a lot heavier.

Another Line Item in BMS's Cutting Spree

BMS isn't just pruning one program. The company has been systematically trimming its pipeline throughout 2025 and 2026 as part of a broader portfolio reshaping effort. Other casualties include MRTX0902, an SOS1 inhibitor inherited from BMS's Mirati acquisition, and EXS4318, a PKC-theta inhibitor from its partnership with Exscientia/Recursion.

The strategy is classic big-pharma portfolio management: kill the lower-conviction bets, redirect resources toward the programs most likely to generate revenue. As of July 2026, BMS still listed 49 compounds in development, so this isn't a company retreating from R&D. It's a company getting pickier about where it spends.

Management has paired these pipeline cuts with broader cost-saving moves, including workforce reductions, facility consolidation, and streamlined trial operations. Think of it like renovating a house: you tear out the rooms that don't work so you can invest in the ones that do.

The DAC Field Just Lost Its Only Proof Point

This is where the story gets bigger than BMS or Orum. ORM-6151 wasn't just another failed drug candidate. It was the only degrader-antibody conjugate to have entered Phase 1 clinical trials. With numerous other DACs in preclinical development globally, the entire field was watching this program for a signal that the approach could work in actual patients.

Now that signal is gone. Some analysts are linking the termination to safety concerns around the DAC platform itself, which raises uncomfortable questions for every company building in this space. If antibody-delivered degraders cause unexpected toxicity, the whole premise of "more precise, less collateral damage" falls apart.

That said, big pharma hasn't abandoned the concept entirely. Roche has a DAC deal with C4 Therapeutics, and Johnson & Johnson acquired Firefly Bio to access similar technology. The interest is still there, but it's now tempered by a very public failure.

What Happens Next

The DAC field just shifted from a "show me the data" story to a "prove it all over again" story. For Orum, the path forward means advancing ORM-1153 and demonstrating that their platform can produce a drug that actually works in humans. For DAC competitors like Nurix Therapeutics and newer entrants, it means preparing for tougher scrutiny from investors and partners who just watched the category's lead program crash.

Partnering and financing for DAC startups will almost certainly get harder in the near term. Pharma companies and investors typically want at least one positive clinical readout before they assign real value to a new drug platform. Right now, DACs have zero.

The science behind targeted protein degradation isn't dead. Other formats in the broader protein degradation space (PROTACs, molecular glues) continue to advance. But for degrader-antibody conjugates specifically, September 2026 will be remembered as the month the field's best chance at clinical validation went up in smoke, along with $100 million of Bristol Myers Squibb's money.

$315M for a Drug That Doesn't Exist Yet

SK Biopharmaceuticals just dropped $315 million on a Parkinson's drug that hasn't even picked its final molecule yet. The dual-target approach is scientifically intriguing, but the timing, right after the field's biggest clinical failure, makes this one of 2026's boldest preclinical bets.